New pill targets Hard-to-Treat cancers with KRAS mutation
NCT ID NCT07718165
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This phase I trial tests an experimental oral drug called ABSK211 in people with advanced solid tumors that have a KRAS gene alteration. The study aims to find a safe dose and see how well the drug works. Participants take ABSK211 by mouth once daily in 21-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental oral drug called ABSK211
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific KRAS gene change.
- What could go wrong
- This is an early, first-in-human trial, so the drug may not be effective or could cause unexpected side effects. The results may not apply to all tumor types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR (PHASE I) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 201321, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.